BioPharm International
March 01, 2016
Cover Story
29
3
Experts in the field share some best practices for optimizing process economics in biomanufacturing.
March 01, 2016
Peer-Reviewed Research
29
3
The authors describe the ways in which manufacturers can mitigate the risks related to the integrity of recombinant transgenes expressed in CHO cells.
March 01, 2016
Downstream Processing
29
3
The necessity to detach cells from a culture substrate during cell harvesting remains one of the most challenging steps in a cell-culture process.
March 01, 2016
Regulatory Beat
29
3
Policy makers debate strategies for promoting access to less costly medicines.
March 01, 2016
Upstream Processing
29
3
Collaborative efforts are underway between suppliers and drug manufacturers to address raw material variability.
March 01, 2016
From the Editor
29
3
Thought leaders tackle drug shortages and biomanufacturing challenges.
March 01, 2016
Features
29
3
Data integrity is a widespread, global problem that must be addressed.
March 01, 2016
Perspectives on Outsourcing
29
3
The biopharmaceutical outsourcing market starts 2016 with company expansions, acquisitions, and new offerings.
March 01, 2016
Features
29
3
Real-time GPS technology, better IT connections, and more conservative, controlled shipping temperatures are improving the shipment of sensitive pharmaceuticals.
March 01, 2016
Ask the Expert
29
3
Susan Schniepp, distinguished fellow, and Andrew Harrison, chief regulatory affairs officer and general counsel, both of Regulatory Compliance Associates, discuss how to create a robust CAPA system and how to identify root cause.
March 01, 2016
Features
29
3
Microbial models offer some exciting production alternatives.
March 01, 2016
Features
29
3
Miniature bioreactors add value by reducing validation efforts.
March 01, 2016
Issue PDF
29
3
Click the title above to open the BioPharm International March 2016 issue in an interactive PDF format.